Pressure From Abroad, Weakening at Home
America’s medical supply is exposed on two fronts. Most of the current conversation only covers one.
The Frontier Goes to Whoever Shows Up
In biotechnology, the contest is not waiting at the border. It runs at the earliest edge of discovery, across borders, in the licensing deals and partnerships where the next generation of medicines first takes shape. That is the frontier. The question for American policy is whether the United States intends to be present on it.
Where we start
I spent more than twenty-five years in national security, most of it as an intelligence officer at the CIA. For the last decade, I focused on China and technology threats, running enterprise risk assessments on its economic and technological strategy and advising senior decision-makers. I retired from the Agency earlier this year. I founded the American Biosecurity Initiative because I kept seeing the same problem from a new angle, and almost no one was naming it correctly.